Current Medicinal Chemistry · 2019 · 76 citations · 43 references
MedicineImmunologyPharmacologyBone MetabolismImmunoregulationImmunotherapyBone HealthImmune Checkpoint InhibitorsOsteoporosisOsteoporosis PharmacotherapyTherapeutic Monoclonal AntibodiesAdministration Of Monoclonal AntibodiesBone Resorption InhibitionBone StrengthCheckpoint Therapeutic AntibodiesImmunological MechanismsImmunological ResponseOsteoimmune InteractionsOsteoimmunology
Osteoporosis is a skeletal pathology characterized by compromised bone strength leading to increased risk of fracture, mainly the spine and hip fractures. Osteoporosis affects more than 200 million people worldwide and because of the skeletal fractures it causes, represents a major cause of morbidity, disability and mortality in older people. Recently, the new discoveries of osteoimmunology have clarified many of the pathogenetic mechanisms of osteoporosis, helping to identify new immunological targets for its treatment opening the way for new and effective therapies with biological drugs. Currently, there are basically two monoclonal antibodies for osteoporosis therapy: denosumab and romosozumab. Here, we focus on the modern approach to the osteoporosis management and in particular, on current and developing biologic drugs targeted to new immunological checkpoints, in the landscape of osteoimmunology.
43
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
Felicia Cosman, Daria B. Crittenden, Jonathan D. Adachi et al. · New England Journal of Medicine · 2016 · 1.7K citations · Full text
Henry G. Bone, Rachel B. Wagman, Maria Luisa Brandi et al. · The Lancet Diabetes & Endocrinology · 2017 · 961 citations · Full text
Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells
Lingling Xian, Xiangwei Wu, Lijuan Pang et al. · Nature Medicine · 2012 · 634 citations · Full text